|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To clarify whether and how PTEN and the PI3K/Akt pathway relates to endometrial carcinoma, we examined the expression of those pathway-related proteins in patients with endometrial carcinoma.
|
11309338 |
2001 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is concluded that the PI 3-K/Akt survival pathway is involved in the regulation of COX-2 and PGE2 synthesis in human endometrial cancer cells.
|
15067356 |
2004 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we elucidated the involvement of the up-regulation of RAS/MAPK and PI3K/AKT cascades in the pathogenesis of endometrial cancer and melanoma by analyzing the genes and molecules in these cascades.
|
16273242 |
2005 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that the PI3K pathway is extensively activated in endometrial carcinomas, and that combination of PIK3CA/PTEN alterations might play an important role in development of these tumors.
|
16322209 |
2005 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results imply that the dysfunction of PTEN leads cells into a less-sensitive phenotype to peptide growth factors by constitutive activation of the PI3K/Akt/PKB signaling pathway in endometrial carcinoma.
|
16525671 |
2006 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockage of PI3K/Akt cascade may become a potential and effective way to control endometrial carcinoma, especially in ER-negative cancers, which show no response to endocrinal therapy.
|
16567092 |
2006 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway are common in endometrial carcinoma.
|
16949921 |
2006 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results indicate that siRNA-mediated gene silencing of PI3K p110-beta may be a useful therapeutic strategy for endometrial cancers overexpressing PI3K p110-beta.
|
17427168 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We searched for alterations in the catalytic domain of PI3K (PIK3CA), PTEN and KRAS, all of which may contribute to PI3K/AKT pathway activation, in a total of 160-familial colorectal (CRC) and endometrial carcinomas (EC), stratified by the presence vs. absence of germline mutations in DNA mismatch repair (MMR) genes.
|
17471559 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulated signaling via the phosphatidylinositol 3-kinase (PI3K) pathway is common in many types of cancer, but its clinicopathological significance in endometrial cancer remains unclear.
|
17924977 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In breast, colon, and endometrial cancers in which the PI3K pathway is activated by a combination of mutant PIK3CA and alterations in Ras, ERBB2/3, or PTEN, signaling to downstream elements such as Akt was mediated exclusively by the p110alpha isoform, rather than a combination of different PI3K isoforms.
|
18829572 |
2008 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
|
19234438 |
2009 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.
|
19261849 |
2009 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of double AKT1/ PTEN mutants is in accord with the hypothesis that in EC more than one hit is required to completely activate the PI3K pathway.
|
19853286 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
|
19917135 |
2009 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed that genomic alterations in the Ras-PI3K pathway are remarkably widespread in endometrial carcinomas, regardless of the type of genomic instability, and suggest that the degree of CIN is a useful biomarker for prognosis in endometrial carcinomas.
|
20062086 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression profiling of 22 genes involved in PI3K-AKT signaling pathway was analyzed in 38 endometrial carcinomas using TaqMan low-density array (TLDA) analysis.
|
20173732 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study analysed the prognostic impact of EGFR family expression in endometrial cancer in relation to PI3K-AKT and MAPK-ERK signalling, as well as drug sensitivity.
|
20664599 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of this study was to determine whether PIK3R1, which encodes p85α, the inhibitory subunit of PI3K, is mutated in endometrial carcinoma.
|
21478295 |
2011 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that HGF possesses chemotactic ability, has anti-apoptosis action, and induces cellular infiltration via the PI3K/Akt pathway; it also triggers NF-κB activation and up-regulates COX-2 gene expression in endometrial cancer cells.
|
21687953 |
2011 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the PI3K pathway represents a critical driver of endometrial cancer pathogenesis and a novel therapeutic target.
|
21984976 |
2011 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
|
22075757 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
|
22146979 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTEN (phosphatase and tensin homolog) is a tumor suppressor that negatively regulates the PI3K-AKT signaling pathway, which is implicated in the pathogenesis of endometrial carcinoma.
|
22301702 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust growth suppression by NVP-BEZ235 suggests that a dual PI3K/mTOR inhibitor is a promising therapeutic for endometrial carcinomas.
|
22662154 |
2012 |